What does “Rescriptor (delavirdine) discontinued” mean for its FDA label?
“Rescriptor” is the brand name for delavirdine, an HIV medicine. If an FDA label was listed as discontinued, it generally means the manufacturer stopped marketing the product or the product was no longer being supplied under that labeled listing, so new prescriptions may no longer be supported through current supply channels under the same label status. The FDA drug-labeling record itself can show status changes when products are withdrawn or discontinued.
If you can share the exact FDA wording you saw (for example, the label status line, the year, or the link), I can interpret it more precisely.
Was delavirdine an NNRTI? (And does FDA labeling still classify it that way?)
Yes. Delavirdine is an NNRTI (non-nucleoside reverse transcriptase inhibitor), a class used in combination antiretroviral therapy for HIV.
Even if the specific marketed product listing is discontinued, the pharmacologic classification as an NNRTI remains accurate based on how the drug works.
Why would an FDA label for an NNRTI like delavirdine be discontinued?
Common reasons include:
- The company stops marketing a formulation or brand due to commercial/supply decisions.
- Lower demand compared with newer antiretroviral options.
- Changes in product availability that lead to withdrawal of the marketed product.
To tie this to delavirdine specifically, the FDA “Drug Shortages”/label history or the manufacturer’s discontinuation notice would be the key document to check.
What does this mean if someone is already taking delavirdine?
For patients already on therapy, the clinical issue is usually treatment continuity. When a drug is discontinued, clinicians typically switch to an alternative fully active regimen or appropriate substitution within established HIV treatment guidelines. The exact best switch depends on viral resistance history and current regimen.
What alternatives replace delavirdine (another NNRTI or different class)?
NNRTI alternatives historically included efavirenz, rilpivirine, and others, but modern regimens often use newer drugs and combinations depending on resistance, prior exposure, and drug–drug interactions. The correct substitution is individualized.
If you tell me whether you’re asking for general information or for a specific patient/regimen context, I can narrow the likely alternatives.
If you meant “nnrti” as “NNRTI,” is there an FDA page that explicitly says that?
The label should identify delavirdine as a non-nucleoside reverse transcriptase inhibitor (NNRTI). If you paste the exact label line you saw (or the FDA identifier), I can confirm what it says and how to interpret it.
---
Sources
I can’t cite specific FDA wording or label pages without the exact FDA record/link or the snippet you saw. If you paste the URL or the exact line from the FDA label status, I’ll answer precisely with citations.